Ann: Positive PDCO opinion and A$20m Placement, page-39

“randomised, double-blind, placebo-controlled study to determine the efficacy, safety, and pharmacokinetic profile of ATL1102 (25 mg and 50 mg) administered once weekly by subcutaneous injection for 52
weeks in non-ambulatory participants with DMD, to be conducted as a potentially pivotal (approvable) trial with a follow-on open label extension trial. Participants will be randomised to either 25 mg ATL1102,”

Don’t worry people .. games being played
”potentially pivotal (approvable) trial”

That means 1 trial away from commercialisation..$$$